Nan Fung Life Sciences
Nan Fung Life Sciences (Pivotal Life Sciences) is a privately held global healthcare investment firm backed by the Nan Fung Group, operating venture capital (bioVenture Partners), venture building in Greater China (bioVenture Partners China), and public equity (Public Equity) strategies for therapeutic-focused life sciences companies and institutional LPs.
- Company typePrivate
- Founded2017
- HeadquartersSan Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Nan Fung Life Sciences does
Nan Fung Life Sciences, operating commercially as Pivotal Life Sciences, is a privately held global healthcare investment platform founded in 2017 with long-term capital backing from the Nan Fung Group. The firm is structured around three investment vehicles: Pivotal bioVenture Partners, a venture capital strategy investing in therapeutic-focused healthcare companies across North America and Europe; Pivotal bioVenture Partners China, a venture-building operation in Greater China covering therapeutics, medical devices, and medical services; and Pivotal Public Equity, launched in 2023 to invest in global small- and mid-cap publicly traded life sciences companies. The firm supports companies "from company creation through clinical development and commercialization," combining deep fundamental research with sector expertise spanning clinical medicine, pharmacology, molecular biology, and biotech consulting.
The platform operates from four offices: a San Francisco headquarters at 501 2nd Street; a Boston-area office at CIC One Broadway in Cambridge, Massachusetts; a regional headquarters in Shanghai (Changning District); and a regional office in Hong Kong's Kai Tak AIRSIDE development. This geographic footprint is designed to source deals across the three principal life sciences innovation hubs of the US, Europe, and Greater China, and to support cross-border syndication and portfolio company operations. Leadership includes founder and managing partner Vincent Cheung, with managing director Peter Bisgaard also referenced.
Pivotal Life Sciences generates revenue through two primary mechanisms typical of alternative asset managers: recurring fund management fees charged to limited partners across its venture and public equity strategies, and performance-based carried interest on successful fund investments. The customer base is bifurcated: institutional investors, family offices, and qualified LPs supplying capital to the funds, and therapeutic-focused healthcare companies (across therapeutics, medical devices, and medical services) seeking growth capital, strategic guidance, and pathways from company formation through commercialization.
Nan Fung Life Sciences firmographics
Firmographics- Name
- Nan Fung Life Sciences
- Legal name
- Pivotal Life Sciences Holdings, LLC
- Website
- https://nanfunglifesciences.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Nan Fung Life Sciences (Pivotal Life Sciences) is a privately held global healthcare investment firm backed by the Nan Fung Group, operating venture capital (bioVenture Partners), venture building in Greater China (bioVenture Partners China), and public equity (Public Equity) strategies for therapeutic-focused life sciences companies and institutional LPs.
- Ownership category
- akta.pro rank
Nan Fung Life Sciences industry classification
Industry- Product category
- Life Sciences Investment Management
- NAICS
- Portfolio Management and Investment Advice (523940)
- SIC
- Security Brokers, Dealers & Flotation Companies (6211), Investment Advice (6282)
- akta.pro primary industry
- Corporate Strategic Real Assets & Infrastructure Venture Investing (FSANAHAN)
Keywords
Where Nan Fung Life Sciences is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Nan Fung Life Sciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Fund Management Fees: Management fees charged to limited partners (LPs) for managing venture capital and public equity funds focused on life sciences investments.
- Carried Interest (Carry): Performance-based carried interest from successful fund investments in portfolio companies, particularly in the venture capital and public equity strategies.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
Nan Fung Life Sciences product offering
Product offeringCore offering
Nan Fung Life Sciences (operating as Pivotal Life Sciences) is a global healthcare investment platform that deploys capital across venture capital and public equity strategies focused on life sciences. The firm provides financing and strategic guidance to companies developing transformative therapeutics, medical devices, and medical services, supporting them from company creation through clinical development and commercialization. Operations span North America, Europe, Greater China, and global public markets, backed by long-term capital commitment from the Nan Fung Group.
Product overview
Pivotal Life Sciences operates as a global healthcare investment platform offering three distinct investment products: Pivotal bioVenture Partners (venture capital for North America and Europe), Pivotal bioVenture Partners China (venture building in Greater China), and Pivotal Public Equity (public market investments in small- to mid-cap life sciences companies). The firm focuses on companies developing high-impact therapeutics to address unmet medical needs, providing financing and guidance from company creation through clinical development and commercialization.
Differentiator
Problem solved
Functional benefit
Products and services
- Pivotal bioVenture Partners Venture capital fund investing in transformative therapeutic-focused healthcare companies across North America and Europe, providing financing and strategic guidance from company creation through clinical development and commercialization. For therapeutic, medical device, and medical services companies seeking growth-stage capital.
- Pivotal bioVenture Partners China Venture building operation specializing in partnering with innovative healthcare companies in the Greater China region, focused on therapeutics, medical devices, and medical services. Invests in and incubates private companies with innovative therapeutic products and platforms addressing substantial unmet medical needs in China.
- Pivotal Public Equity Public equity investment strategy focusing on undervalued publicly listed companies with innovative therapeutics, devices, or biomedical tools in the global small- to mid-cap space. Identifies companies with specific catalysts for long-term risk-adjusted returns.
Companies that use Nan Fung Life Sciences
Customer profileSegments2 records
Ideal customer profiles2 records
Nan Fung Life Sciences technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Nan Fung Life Sciences partnerships and signals
Strategic signalRecent moves4 records
Expansion highlights4 records
Nan Fung Life Sciences competitors and assessment
Company assessmentDirect peers
- Atlas Venture: Boston/Cambridge-based early-stage life-sciences venture firm building companies from inception. Directly comparable to Pivotal bioVenture Partners' North American strategy.
- ARCH Venture Partners: Long-tenured US biotech VC firm investing in transformative therapeutics across stages. Comparable to Pivotal bioVenture Partners in therapeutic focus and stage-agnostic approach.
- Flagship Pioneering: US-based biotech venture creator originating and building therapeutic companies from novel platforms. Directly comparable to Pivotal bioVenture Partners' company-creation and platform focus.
- Perceptive Advisors: Healthcare-focused crossover investment firm with venture and public-equity strategies. Directly comparable to Pivotal's combined private/public life-sciences model.
- OrbiMed: One of the world's largest healthcare-dedicated investment firms managing both private venture and public-equity strategies. Directly comparable to Pivotal's multi-strategy healthcare VC + public equity model.
- RA Capital Management: Boston-based healthcare-focused investment manager running crossover and public-equity funds investing across the life-sciences capital structure. Comparable to Pivotal's public-equity and private crossover orientation.
- Baker Bros. Advisors: Healthcare-focused long-only manager with both private (Baker Bros. Life Sciences) and public-equity vehicles, investing across all stages of therapeutic development. Closely mirrors Pivotal's two-strategy private/public life sciences model.
- Andreessen Horowitz Bio + Health: Major US venture firm with dedicated bio/health fund investing across therapeutic stages and digital health. Comparable in scale and ambition to Pivotal's North American VC strategy.
- Vivo Capital: Healthcare-focused investment firm with strong US-Asia cross-border activity and venture, growth, and public-equity capabilities. Closely comparable to Pivotal's US/China cross-border platform.
Regional players
- Hillhouse Capital (HHLR): Asia-based, particularly Greater China, multi-strategy asset manager with dedicated healthcare/biotech investment capabilities. Comparable to Pivotal bioVenture Partners China strategy.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Nan Fung Life Sciences social profiles
Digital presenceNan Fung Life Sciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nan Fung Life Sciences leadership team
Management profileNumber of profiles
Profiles2 records
Nan Fung Life Sciences funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nan Fung Life Sciences M&A and investment
M&A and investmentM&A
Investments27 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nan Fung Life Sciences
What does Nan Fung Life Sciences do?
Nan Fung Life Sciences (operating as Pivotal Life Sciences) is a global healthcare investment platform that deploys capital across venture capital and public equity strategies focused on life sciences. The firm provides financing and strategic guidance to companies developing transformative therapeutics, medical devices, and medical services, supporting them from company creation through clinical development and commercialization. Operations span North America, Europe, Greater China, and global public markets, backed by long-term capital commitment from the Nan Fung Group.
Is Nan Fung Life Sciences a public or private company?
Nan Fung Life Sciences is a private company. It is classified as corporate owned and is currently operating.
When was Nan Fung Life Sciences founded?
Nan Fung Life Sciences was founded in 2017. It employs 1 to 10 people.
Where is Nan Fung Life Sciences based?
Nan Fung Life Sciences is headquartered in San Francisco, United States, in the North America region.
How does Nan Fung Life Sciences make money?
Two revenue lines are on record. Fund Management Fees are the primary driver. The others are carried Interest (Carry).
Who are Nan Fung Life Sciences's main competitors?
Direct peers on record are Atlas Venture, ARCH Venture Partners, Flagship Pioneering, Perceptive Advisors, OrbiMed, RA Capital Management, Baker Bros. Advisors, Andreessen Horowitz Bio + Health and Vivo Capital. Hillhouse Capital (HHLR) is listed as a regional player.
Does Nan Fung Life Sciences have an API?
No public API is recorded for Nan Fung Life Sciences.
What industry is Nan Fung Life Sciences in?
Nan Fung Life Sciences's product category is Life Sciences Investment Management. Its primary akta.pro industry code is FSANAHAN, Corporate Strategic Real Assets & Infrastructure Venture Investing. Its NAICS code is 523940 and its SIC code is 6211.